MetaCap

Mangoceuticals Inc. (MGRX)

NASDAQ: MGRXHealth CareMisc Health and Biotechnology ServicesUSD

0.1236-0.0101 (-7.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MGRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.52
52-week range
0.121 – 1.38
Day range
0.1213 – 0.1371
Volume / Avg
241.10K / 638.90K
Beta
—

52-week range

$0.121$1.38

MGRX stock today

Mangoceuticals (MGRX) closed at $0.1236 on Nov 20, down 7.55% (-$0.0101), versus the S&P 500's 3.70% decline. Trading was light, with 241.10K shares changing hands, about 38% of the average daily volume. At this level, MGRX sits near the bottom of its 52-week range of $0.121 to $1.38: 91.0% below the high and 2.1% above the low.

Mangoceuticals has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Mangoceuticals

Company profile

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.

Industry
Misc Health and Biotechnology Services
CEO
Mr. Jacob D. Cohen
Headquarters
Dallas, TX
Employees
3
IPO year
2023

Financial highlights

Full financials

In fiscal 2025, Mangoceuticals generated $456,021 in revenue, down 26.0% from fiscal 2024, its first annual decline since 2024. Mangoceuticals reported a net loss of $20.6 million, compared with a loss of $8.7 million a year earlier. Gross margin was 54.9% (down from 61.7%) and operating margin -3954.3%.

Mangoceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$456.02K$615.87K$731.49K$8.94K
Growth-25.96%-15.81%+8083.16%—
Net income$-20.64M$-8.71M$-9.21M$-2.00M
EPS (diluted)$-2.17$-4.80$-8.58$-0.19

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.18 vs —

MGRX news

All MGRX news

Mangoceuticals peers

Health Care sector
MGRX peer companies
CompanyPrice% ChgMarket capCompare
NIVFNewGenIvf Group Limited Class A0.0269-23.14%$80.77Kvs MGRX
CCELCryo-Cell International Inc.4.150.00%$33.46Mvs MGRX
PARKPark Dental Partners Inc.17.03-6.79%$94.26Mvs MGRX
VMDViemed Healthcare Inc.8.52-1.05%$322.85Mvs MGRX
AGLagilon health inc.90.24+0.83%$1.52Bvs MGRX
PGNYProgyny Inc.35.71+0.73%$2.63Bvs MGRX
SHCSotera Health Company15.91-1.85%$4.54Bvs MGRX
DVADaVita Inc.161.03+3.00%$10.13Bvs MGRX

Indexes, lists and sector

Mangoceuticals stock FAQ

What is Mangoceuticals's stock price today?

MGRX last traded at $0.1236 as of Nov 20, 4:00 PM EST, down 7.55% on the day. Prices are delayed at least 15 minutes.

Who is Mangoceuticals's CEO?

Mr. Jacob D. Cohen is the chief executive officer of Mangoceuticals Inc., which has about 3 employees.

What is the MGRX 52-week high?

The 52-week high for MGRX is $1.38 and the 52-week low is $0.121. The stock is currently 91.0% below its high.

Compare MGRX